Analysis of CXCL8 and its receptors CXCR1/CXCR2 at the mRNA level in neoplastic tissue, as well as in serum and peritoneal fluid in patients with ovarian cance.
CXCL8 chemokine
CXCR1/CXCR2 receptors
ovarian cancer
Journal
Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
25
04
2022
accepted:
29
06
2022
entrez:
3
8
2022
pubmed:
4
8
2022
medline:
5
8
2022
Statut:
ppublish
Résumé
Understanding the relationship between the coexistence of inflammatory and neoplastic processes in ovarian cancer, particularly those involving chemokines and their receptors, may help to elucidate the involvement of the studied parameters in tumor pathogenesis and could lead to improved clinical applications. Therefore, the present study aimed to analyze the levels of C‑X‑C motif chemokine ligand 8 (CXCL8), and its receptors C‑X‑C chemokine receptor (CXCR)1 and CXCR2, in the serum and peritoneal fluid of women with ovarian cancer, and to evaluate the association between the expression of these parameters in tumor tissue and patient characteristics, particularly the degree of histological differentiation. The study group included women with ovarian cancer diagnosed with serous cystadenocarcinoma International Federation of Gynecology and Obstetrics stage IIIc and a control group, which consisted of women who were diagnosed with a benign lesion (serous cystadenoma). The transcript levels of
Identifiants
pubmed: 35920183
doi: 10.3892/mmr.2022.12812
pii: 296
pmc: PMC9435018
doi:
pii:
Substances chimiques
Interleukin-8
0
RNA, Messenger
0
Receptors, Interleukin-8A
0
Receptors, Interleukin-8B
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Cell Mol Med. 2020 Jan;24(2):1588-1598
pubmed: 31793192
Clin Cancer Res. 2016 Aug 1;22(15):3924-36
pubmed: 26957562
Int J Mol Sci. 2020 May 24;21(10):
pubmed: 32456359
Cancer Cell. 2020 Nov 9;38(5):598-601
pubmed: 33038939
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188503
pubmed: 33421585
J Oncol. 2021 Jan 28;2021:8859554
pubmed: 33763130
Aging (Albany NY). 2021 May 26;13(10):13405-13420
pubmed: 34038868
Molecules. 2021 Dec 27;27(1):
pubmed: 35011369
Gynecol Oncol. 2020 Aug;158(2):484-488
pubmed: 32518015
ISRN Oncol. 2013 Oct 09;2013:859154
pubmed: 24224100
Front Immunol. 2020 Oct 06;11:577869
pubmed: 33123161
Mol Diagn Ther. 2013 Jun;17(3):139-46
pubmed: 23552992
Theranostics. 2017 Apr 7;7(6):1543-1588
pubmed: 28529637
Oncotarget. 2015 Oct 13;6(31):31593-603
pubmed: 26267317
Oncol Lett. 2019 Feb;17(2):2365-2369
pubmed: 30719112
Math Biosci Eng. 2015 Dec;12(6):1203-17
pubmed: 26775857
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Commun. 2018 Apr 27;9(1):1685
pubmed: 29703902
Hum Vaccin Immunother. 2020 Oct 2;16(10):2312-2317
pubmed: 31860375
Chin Clin Oncol. 2020 Aug;9(4):47
pubmed: 32648448
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Sci Rep. 2018 Aug 17;8(1):12394
pubmed: 30120290
Oncogene. 2016 Aug 4;35(31):4036-47
pubmed: 26657155
Cancers (Basel). 2018 Jul 30;10(8):
pubmed: 30061485
Br J Cancer. 2019 Nov;121(11):934-943
pubmed: 31673102
Aging (Albany NY). 2020 Jan 27;12(2):1928-1951
pubmed: 31986121
BMC Cancer. 2011 May 30;11:210
pubmed: 21619709
Cytokine Growth Factor Rev. 2016 Oct;31:61-71
pubmed: 27578214
Cytokine. 2013 Oct;64(1):413-21
pubmed: 23727325
Diagnostics (Basel). 2021 Mar 07;11(3):
pubmed: 33800113
J Ovarian Res. 2019 Dec 06;12(1):120
pubmed: 31810474
Am J Reprod Immunol. 2020 Dec;84(6):e13309
pubmed: 32698242
Clin Cancer Res. 2008 Nov 1;14(21):6735-41
pubmed: 18980965
Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38
pubmed: 29249039
Br J Cancer. 2020 Oct;123(9):1404-1416
pubmed: 32778818
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Front Immunol. 2019 Apr 12;10:757
pubmed: 31031757
Cancer Manag Res. 2020 Sep 14;12:8435-8443
pubmed: 32982437
Int J Oncol. 2021 May;58(5):
pubmed: 33649784